Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), RegenXBio (RGNX) and Vera Therapeutics (VERA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), RegenXBio (RGNX – Research Report) and Vera Therapeutics (VERA – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Anavex Life Sciences (AVXL)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences today and set a price target of $42.00. The company’s shares closed last Monday at $9.61.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.6% and a 57.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'>

Anavex Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $42.00.

See today’s best-performing stocks on TipRanks >>

RegenXBio (RGNX)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on RegenXBio today and set a price target of $34.00. The company’s shares closed last Monday at $10.69.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.7% and a 43.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Bausch + Lomb Corporation, and Barinthus Biotherapeutics. ;'>

RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $25.67.

Vera Therapeutics (VERA)

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Vera Therapeutics, with a price target of $75.00. The company’s shares closed last Monday at $30.94.

According to TipRanks.com, Clark-Gartner is a 4-star analyst with an average return of 17.8% and a 67.4% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Rocket Pharmaceuticals, and Mirum Pharmaceuticals. ;'>

Vera Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $78.00, a 158.8% upside from current levels. In a report issued on September 30, J.P. Morgan also maintained a Buy rating on the stock.

Read More on AVXL:

Disclaimer & DisclosureReport an Issue

• Anavex announces development of oral tablet formulation for ANAVEX3-71 program
• Anavex announces Phase 2 study of ANAVEX3-71 met its primary endpoint
• Anavex announces publication on oral blarcamesine Phase IIb/III trial
• Promising Clinical Data and Market Potential Drive Buy Rating for Anavex Life Sciences
• Anavex announces latest findings for blarcamesine